Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. director Kimberly Manhard received a grant of stock options covering 15,000 shares of common stock. The options carry an exercise price of $95.22 per share and will be fully exercisable on June 3, 2027, subject to her continued service through that date.

Following this grant, she holds stock options for 15,000 underlying shares directly. This award is compensation-related and was not an open-market purchase or sale of existing shares.

Insights

Equity compensation and governance analyst

Routine director option grant with future vesting, no open-market trading.

Inhibrx Biosciences granted director Kimberly Manhard stock options for 15,000 shares of common stock with a $95.22 exercise price. The award is classified as a grant or other acquisition, not a market transaction, and reflects standard equity-based compensation.

The options become fully exercisable on June 3, 2027, contingent on continued service. This structure aligns the director’s potential upside with future company performance over the vesting period, but does not itself change cash flow since the exercise, if it occurs, would come later.

The filing shows 15,000 option shares following this transaction, with no additional derivative positions listed. Future company disclosures would indicate if and when any portion of these options is exercised or if further equity awards are granted.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MANHARD KIMBERLY

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 15,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 15,000 shares Exercise price: $95.22 per share Total options after grant: 15,000 shares +2 more

5 metrics

Option grant size 15,000 shares Stock options underlying common stock granted to director

Exercise price $95.22 per share Stock option exercise price for granted options

Total options after grant 15,000 shares Total option shares held following transaction

Vesting date June 3, 2027 Options fully exercisable on this date, subject to service

Option expiration June 3, 2036 Expiration date of the stock options

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, fully exercisable, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 95.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully exercisable financial

"This stock option will be fully exercisable on June 3, 2027"

continued service regulatory

"subject to the reporting person's continued service through such date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MANHARD KIMBERLY

(Last) (First) (Middle)

C/O INHIBRX BIOSCIENCES, INC.

11025 NORTH TORREY PINES ROAD, SUITE 140

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibrx Biosciences, Inc. [ INBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$95.22	06/03/2026		A		15,000		06/03/2027(1)	06/03/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Remarks:

	/s/ Kelly D. Deck, as attorney-in-fact for Kimberly Manhard	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Inhibrx Biosciences (INBX) director Kimberly Manhard receive in this Form 4?

She received a grant of stock options for 15,000 shares of common stock. These options are part of her equity compensation and do not represent an open-market share purchase or sale by the director.

What is the exercise price of the Inhibrx Biosciences (INBX) options granted to Kimberly Manhard?

The granted stock options have an exercise price of $95.22 per share. This is the price she would pay per share if she later chooses to exercise the options after they become fully exercisable.

When do Kimberly Manhard’s Inhibrx Biosciences (INBX) stock options vest?

The stock options will be fully exercisable on June 3, 2027. Vesting is subject to her continued service with Inhibrx Biosciences through that date, as noted in the Form 4 footnote.

How many Inhibrx Biosciences (INBX) option shares does Kimberly Manhard hold after this transaction?

After this grant, she holds stock options covering 15,000 underlying shares of common stock. This reflects the total derivative position reported in this Form 4 for the director following the award.

Does this Inhibrx Biosciences (INBX) Form 4 show any share sales or purchases by Kimberly Manhard?

No, the Form 4 reports only a grant of stock options classified as a grant, award, or other acquisition. It does not show any open-market share purchases or sales by the director in this filing.